Stuttgart
04.03.26 | 21:55
16,900 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 16,890 | 17,400 | 04.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02. | XVIVO Perfusion AB: The Nomination Committee's Proposal for New Board Members | 1.503 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Correction: In the press release that was distributed today at 2:00 p.m. CET, the nomination... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 19.02. | XVIVO Perfusion AB: Management Change at XVIVO - CFO Transitions to New Role | 240 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / February 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO Perfusion AB (publ) today announces that the company's CFO, Kristoffer Nordström... ► Artikel lesen | |
| 10.02. | XVIVO Perfusion AB: Change of Date for Publication of the Interim Report January-March 2026 | 213 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / February 10, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)XVIVO Perfusion AB (publ) has decided to postpone the publication of its interim report for... ► Artikel lesen | |
| 27.01. | XVIVO Perfusion AB: Year-End Report 2025 | 294 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2025 (Oct-Dec)Net sales amounted to SEK 226.1 million (227.6), corresponding to... ► Artikel lesen | |
| 15.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2025 | 278 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 15, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| 06.01. | XVIVO Perfusion AB: XVIVO's CEO to present at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco | 256 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 6, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announced its participation in the 44th annual J.P. Morgan Healthcare Conference... ► Artikel lesen | |
| 23.10.25 | XVIVO Perfusion AB: Interim Report January-September 2025 | 307 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2025 (Jul-Sep)Net sales amounted to SEK 189.1 million (198.5), corresponding to growth... ► Artikel lesen | |
| 13.10.25 | XVIVO Perfusion AB: Conference Call on Interim Report July-September 2025 | 371 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September... ► Artikel lesen | |
| 05.09.25 | Nomination Committee of XVIVO Perfusion AB | 312 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general... ► Artikel lesen | |
| 28.07.25 | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 683 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 21.07.25 | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 375 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| 11.07.25 | XVIVO Perfusion AB: Interim Report January-June 2025 | 455 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 10.07.25 | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 439 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06.25 | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 379 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04.25 | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 397 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04.25 | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 506 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04.25 | XVIVO Perfusion AB: Interim Report January-March 2025 | 369 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04.25 | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 479 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04.25 | XVIVO Perfusion AB: Annual Report 2024 | 556 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03.25 | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 448 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,210 | +3,54 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler kooperiert mit Molecular Partners bei der Entwicklung von Radio-DARPin-Therapeutika | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Kooperation/Vereinbarung
Eckert & Ziegler kooperiert mit Molecular Partners bei der Entwicklung von Radio-DARPin-Therapeutika
26.02.2026... ► Artikel lesen | |
| UNITEDHEALTH | 250,80 | +0,08 % | UnitedHealth-Aktie: Erholung in Sicht - Was Anleger jetzt wissen müssen | ||
| INTUITIVE SURGICAL | 430,90 | +0,06 % | Intuitive Surgical: Steht ein weiterer Rücksetzer bevor? | Die Intuitive-Surgical-Aktie zeigt seit dem Jahreswechsel eine deutlich schwächere Struktur. Rutscht der Kurs in Richtung der nächsten Unterstützung ab Den vollständigen Artikel lesen ... ► Artikel lesen | |
| RHOEN-KLINIKUM | 12,700 | 0,00 % | EQS-PVR: RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.02.2026... ► Artikel lesen | |
| HIMS & HERS HEALTH | 14,200 | +0,50 % | Hims & Hers back in red as FDA doubles down on GLP-1 compounders | ||
| BICO GROUP | 1,621 | -0,73 % | BICO Group AB: Publication of BICO Group AB: Year-end report 2025 | Strong Lab Automation growth and higher cash balance
Q4 2025 SummaryLab Automation delivered 15 percent organic sales growth YoY. This was primarily driven by accelerated project completions and additional... ► Artikel lesen | |
| M1 KLINIKEN | 15,900 | -3,64 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| BAXTER | 16,552 | +1,22 % | Dividendenbekanntmachungen (27.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,38 USD 0,322 EUR AGNC INVESTMENT CORP US00123Q1040 0,12 USD 0,1017 EUR AGREE REALTY CORPORATION US0084921008 0... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 5,450 | -0,91 % | Aktie von JD Health büßt 2,73 Prozent ein (7,125 €) | An der Börse notiert die JD Health-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 7,13 Euro. Die Aktie von JD Health verzeichnet gegenwärtig einen Kursrückgang von 2,73... ► Artikel lesen | |
| LIFEWARD | 6,780 | 0,00 % | Lifeward Ltd. - 8-K, Current Report | ||
| COOPER COMPANIES | 70,50 | 0,00 % | Cooper Companies' Earnings Outlook | ||
| SURGICAL SCIENCE SWEDEN | 3,022 | -0,59 % | Surgical Science Sweden AB: Year-end report 2025: Profitability in line with financial targets | Fourth quarter 2025 (October - December)Net sales amounted to SEK 268.9 (251.5) million, an increase of 7 percent compared with the corresponding period in the preceding year. Calculated in local currencies... ► Artikel lesen | |
| ONWARD MEDICAL | 4,175 | +0,36 % | ONWARD Medical NV: ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury | Empower BP is a landmark global pivotal study evaluating the safety and effectiveness
of the implantable ARC-IM System
to address blood pressure instability after spinal cord injury (SCI)Blood... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,560 | +0,44 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments... ► Artikel lesen |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 16,900 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.